BioForest

Found 21,761 articles

• 

  BioSpace Launches 2022 Hotbed Maps to Highlight Thriving Life Sciences Clusters

  1/18/2022

  As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.

• Outpace Bio Expands Seattle Presence with Cell Therapy Research Hub & Collaborations with Leading Experts in Protein Design & Cancer Immunotherapy

  5/22/2023

  Outpace Bio, a company using protein design and cell engineering to create advanced cell therapies with curative potential, announced the expansion of its research facilities and new collaborations with leading scientists at Fred Hutchinson Cancer Center and the Institute for Protein Design at the University of Washington School of Medicine.

• Icosavax Announces Positive Topline Interim Phase 1 Results for Bivalent VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults

  5/22/2023

  Icosavax, Inc. (Nasdaq: ICVX) today announced positive topline interim results from its Phase 1 clinical trial of IVX-A12 against respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in older adults.

• Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer

  5/22/2023

  Athira Pharma, Inc. today announced the appointment of Andrew Gengos as Chief Financial Officer and Chief Business Officer, effective immediately.

• Icosavax Announces $67.8 Million Registered Direct Offering of Common Stock

  5/22/2023

  Icosavax, Inc. announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 8,369,754 shares of its common stock at a purchase price of $8.10 per share.

• NanoString to Host Conference Call on Monday, May 22, 2023, to Provide Comments on Decision of the Regional Court of Munich

  5/22/2023

  NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced that the Company will host a conference call on Monday, May 22, 2023, at 4:30pm ET to provide an update on the recent Decision of the Regional Court of Munich.

• Tune Therapeutics Unveils Breakthrough Data Showing Stable and Durable Epigenetic Regulation in Non-Human Primates

  5/22/2023

  At the 26th Annual Meeting of the American Society of Gene & Cell Therapy, leading epigenetic editing company Tune Therapeutics showcased the power and potential of its TEMPO TM genetic tuning platform, by presenting data showing the stable repression of the PCSK9 gene and the effective reduction of LDL-cholesterol levels in non-human primates.

• Alpine Immune Sciences to Present Data from RUBY-1, a Phase 1 Study of Povetacicept, at Upcoming Scientific Congresses

  5/19/2023

  Alpine Immune Sciences, Inc. (NASDAQ: ALPN) announced the Company will present data from RUBY-1, a phase 1 study of povetacicept in healthy adult volunteers, at multiple upcoming scientific congresses, including participation in a poster tour at the European Congress of Rheumatology (EULAR) and an oral presentation at the European Hematology Association (EHA).

• OncoResponse Awarded $13 Million in Funding from CPRIT and Raises $14 Million in Added Funds from Investors to Advance Cancer Immunotherapy

  5/18/2023

  OncoResponse today announced it has been awarded a $13 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

• Tasso Recommended for Certification from Medical Device Single Audit Program (MDSAP)

  5/18/2023

  Tasso, Inc. today announced that it has been recommended for certification from the Medical Device Single Audit Program (MDSAP), under which a single regulatory audit of a medical device manufacturer may satisfy the requirements of multiple regulatory jurisdictions participating in the program.

• From Seattle to Space: Science that Began at the Allen Institute Blasts off to International Space Station

  5/18/2023

  This Sunday at 2:37 p.m. PDT1, astronauts from Axiom Space in partnership with Cedars-Sinai will blast off to the International Space Station carrying cells from the Allen Institute for Cell Science, a division of the Allen Institute.

• Dr. Linda Tolbert selected as executive medical director for the Washington Permanente Medical Group

  5/18/2023

  A new era has launched for the Washington Permanente Medical Group, with the selection of its new executive medical director, Linda Tolbert, MD, JD, EdD, MPH, who officially began her position on May 15, 2023.

• Outpace Bio to Present New Data on OutSmart™ IL-2/15, a CAR T Cell-Produced Designed Cytokine with Tumor-Localized Immune Cell Activity, at the 2023 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

  5/18/2023

  Outpace Bio today announced it will present advancements to its OutSmartTM platform during a poster presentation at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual meeting being held from May 16-20, 2023 in Los Angeles, CA.

• Ozette Announces New Suite of Machine Learning-Powered Computational Analysis Solutions Coupled with High Dimensional Full Spectrum Cytometry Data Generation to Accelerate Decision-Making for Clinical Biomarker Teams

  5/18/2023

  Ozette Endpoints™ delivers the fastest path from cytometry data to actionable results enabling clinical development teams to answer key biomarker questions to support pharmacodynamics, safety, and disease biology objectives.

• Cadence Neuroscience Secures $26 Million in Series B Financing for Clinical Trials of Epilepsy Neuromodulation Therapy

  5/17/2023

  Cadence Neuroscience announced today that it has secured $26 million in Series B financing.

• Dr. Jay Evans, Inimmune Co-Founder and Chief Scientific and Strategy Officer, will be featured as a keynote speaker at the ITHS/WE-REACH Expo '23 in Seattle, WA on May 18, 2023

  5/17/2023

  Inimmune announced that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., will be a Keynote speaker at the University of Washington, Institute for Translational Health Sciences Expo '23.

• Lumen Bioscience Receives Fast Track Designation from U.S. FDA for LMN-201

  5/17/2023

  Lumen Bioscience today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for LMN-201, an investigational, orally delivered biologic drug to treat and prevent C. difficile infection (CDI).

• Indapta Therapeutics Announces U.S. FDA Clearance of IND for IDP-023, an Allogeneic Natural Killer (NK) Cell Therapy for Cancer

  5/17/2023

  Indapta Therapeutics, Inc. today announced that the company has reached agreement with the U.S. Food and Drug Administration (FDA) on an Investigational New Drug (IND) application to commence its first-in-human phase 1 trial in patients with multiple myeloma and lymphoma anticipated to begin in the second half of 2023.

• Umoja Biopharma Presents New Preclinical Data at the American Society of Gene and Cell Therapy 26th Annual Meeting Demonstrating Potent In Vivo CAR T Cell Generation and Durable Anti-Tumor Activity

  5/17/2023

  Umoja Biopharma, Inc. today announced the presentation of new preclinical data at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting demonstrating potent in vivo CAR T cell generation and robust anti-tumor activity using its VivoVec™ platform.

• Chinook Therapeutics Announces Partnership with Ionis to Develop Antisense Therapy for Rare, Severe Chronic Kidney Disease

  5/16/2023

  Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced it has entered a collaboration agreement with Ionis Pharmaceuticals, Inc. for the discovery, development and commercialization of an antisense oligonucleotide (ASO) therapy for a rare, severe chronic kidney disease with significant unmet medical need.